TL;DR
This study reveals that Left Ventricular Systolic Dysfunction (LVSD), a common heart condition, significantly worsens outcomes for patients receiving thrombolysis treatment for acute ischemic stroke. Individuals with LVSD face higher mortality, increased risk of heart failure and heart attack, and poorer functional recovery after stroke.
What Problem Does This Paper Address?
Acute Ischemic Stroke (AIS) is a major cause of death and disability. Intravenous (IV) thrombolysis is a critical treatment, but its effectiveness can be influenced by various patient factors. While the link between heart disease and stroke risk is known, the specific impact of Left Ventricular Systolic Dysfunction (LVSD) – a condition where the heart's main pumping chamber doesn't contract effectively – on outcomes after thrombolysis for AIS has been poorly understood. This lack of clarity hinders optimal patient management and risk stratification.
Methods
The researchers conducted a retrospective observational study, analyzing data from 937 consecutive patients who received IV thrombolysis for AIS between 2006 and 2018. LVSD was defined as a Left Ventricular Ejection Fraction (LVEF) below 50%. They used statistical methods to compare outcomes between patients with and without LVSD. This included:
- Univariate and multivariate binary logistic regression: To analyze demographic characteristics and identify independent predictors of LVSD.
- Ordinal shift regression: To assess functional outcomes, specifically the Modified Rankin Scale (mRS) at 3 months, which measures disability.
- Survival analysis (Cox proportional hazards model): To evaluate the risk of mortality, heart failure (HF) admission, myocardial infarction (MI), and recurrent stroke/transient ischemic attack (TIA).
Datasets
The study utilized data from a single tertiary academic center, drawing from the Computerized Patient Support System. The dataset comprised 937 patients who underwent IV thrombolysis for AIS and had a transthoracic echocardiogram (TTE) performed within 6 months of their stroke event.
Key Insights and Ideas
- The "Stroke-Heart Syndrome" is more than just a risk factor: This study strongly suggests that pre-existing LVSD isn't just a risk factor for stroke, but a significant determinant of how poorly a patient recovers after receiving life-saving thrombolysis.
- LVSD is a harbinger of multiple adverse events: It's not just about stroke recovery; LVSD patients are at a significantly higher risk for subsequent cardiac events like heart failure and heart attacks, compounding their health challenges.
- Functional recovery is significantly hampered: The impact on daily living is substantial. LVSD patients are less likely to regain independence after their stroke, highlighting the broader implications for quality of life and long-term care needs.
- Recurrent stroke risk isn't directly linked: Interestingly, while LVSD impacts overall mortality and cardiac events, it didn't show a significant association with recurrent stroke or TIA in this cohort, suggesting other factors might be more dominant for stroke recurrence.
Key Results
- Higher Comorbidity Burden: Patients with LVSD were more likely to have diabetes mellitus, atrial fibrillation, and ischemic heart disease compared to those with normal LVEF.
- Worse Functional Outcomes: LVSD was associated with significantly worse functional outcomes at 3 months, as measured by the mRS. The adjusted odds ratio for an unfavorable shift in mRS was 1.41 (p=0.030).
- Increased Mortality: LVSD was a strong independent predictor of all-cause mortality, with an adjusted hazard ratio (aHR) of 3.38 (p < 0.001).
- Elevated Cardiac Event Risk: Patients with LVSD had a significantly higher risk of subsequent heart failure admission (aHR 4.23, p < 0.001) and myocardial infarction (aHR 2.49, p = 0.001).
- No Increased Recurrent Stroke Risk: LVSD did not significantly predict recurrent stroke or TIA events (aHR 1.15, p = 0.496).
Limitations and Future Work
The authors acknowledge several limitations:
- Retrospective Design: The study design means they can show associations but cannot definitively prove causation.
- Single-Center Study: The findings may not be generalizable to all patient populations and require validation in larger, multi-center studies.
- Loss to Follow-up: Patients might have sought treatment elsewhere, leading to potential bias in outcome tracking.
- Limited Baseline Data: The study lacked detailed information on specific HF etiologies, New York Heart Association (NYHA) class, NT-proBNP levels, and baseline medications, which could provide a more nuanced understanding of HF's contribution.
- LVSD Definition: Defining LVSD solely by LVEF < 50% might overlook other aspects of cardiac dysfunction.
Future research should focus on:
- Investigating strategies to optimize LVEF in AIS patients.
- Exploring the role of cardiovascular prevention medications in AIS patients with LVSD, particularly those with AF and IHD.
- Conducting prospective studies to establish causality and explore the underlying mechanisms of the stroke-heart interaction.
- Comparing echocardiographic markers as predictors for recurrent stroke.
Summary updated